Application of composition containing cordyceps militaris extract in preparation of product for preventing and treating colitis

Abstract

The invention discloses application of a composition containing a cordyceps militaris extract to preparation of a product for preventing and treating colitis. The composition comprises the cordyceps militaris extract, an astragalus extract, a sanguisorba officinalis extract and a rhizoma bletillae extract. The composition provided by the invention aims to relieve swelling and pain, nourish yin and clear heat, and tonify spleen and warm kidney, promotes intestinal mucosal barrier repair, quickly relieves inflammatory response, and cures or improves colitis.

Description

Technical Field

[0001] The invention relates to the field of biomedicine, and in particular to application of a composition containing a Cordyceps militaris extract in preparing a product for preventing and treating colitis. Background Art

[0002] This section merely provides background information related to the present disclosure and is not necessarily prior art.

[0003] Colitis is a stubborn digestive disease of unknown cause, clinically characterized by abdominal pain, painful diarrhea, mucus and blood in the stool, etc., with a long course and easy recurrence. In recent years, the incidence of ulcerative colitis has been on the rise worldwide and is positively correlated with economic development. How to safely and effectively prevent and treat colitis has become one of the focuses of digestive medicine workers.

[0004] The name of ulcerative colitis is not found in ancient Chinese medical books. According to the symptoms and pathogenesis, it can be classified into the categories of "chronic diarrhea" and "chronic dysentery" in traditional Chinese medicine. About the understanding of "diarrhea". Since ancient times, doctors of all dynasties have divided the causes of colitis into two categories: internal and external causes. The internal causes are mainly internal injuries from diet, emotional frustration, and internal injuries from fatigue, while the external causes are mainly external six evil spirits. Traditional Chinese medicine believes that colitis has seven syndromes: spleen deficiency and dampness, large intestine dampness and heat, blazing heat and toxicity, yin and blood deficiency, mixed cold and heat, liver depression and spleen deficiency, and spleen and kidney yang deficiency. Among them, spleen deficiency and kidney deficiency are the key to the onset of the disease. Zhang Jingyue: "The root of diarrhea is all from the spleen and stomach." He pointed out that the root of diarrhea is weak spleen and stomach. In the Complete Book of Jingyue, Xiexie, it is mentioned that "the kidney is the gate of the stomach, ... the opening and closing of the stool are all controlled by the kidney ... the yin qi is extremely strong ... it makes people have diarrhea." It is pointed out that the kidney controls the two excretions and opens the orifices in the front and back two yin. Congenital kidney yang deficiency or old and weak, insufficient yang qi, life gate fire decline, kidney fire cannot generate spleen and earth, resulting in normal digestion of water and food, causing diarrhea. When the kidney qi is full, the kidney's gasification function is normal and the two excretions are normal; when the kidney yang qi is weak, the gate is not solid, which can cause long-term diarrhea and slipping. Therefore, the treatment of colitis must start with regulating the yin and yang of the spleen and kidney, and adjusting the balance of qi and blood in the body to achieve the effect of treating both the symptoms and the root cause. For example, the Chinese invention application CN1285213A discloses a Chinese patent medicine for treating colitis and its preparation method, which is prepared by mixing snow gall, catechu, licorice, coptis root, and Yuanhu powder. However, its heat-clearing and damp-drying, purging fire and detoxification ignores the importance of strengthening the spleen and warming the kidney.

[0005] The pathogenesis of colitis is still unclear, but it mainly involves intestinal microbial imbalance, abnormal immune response, intestinal mucosal barrier dysfunction, infection, genetics and other aspects. Modern medicine has achieved certain results in the treatment of colitis, but the treatment cycle is long and it cannot completely cure colitis. The treatment is more mechanical and does not pay attention to individual differences. In addition, long-term medication puts considerable pressure on the patient's body and economy, which has its limitations. In contrast, traditional medicine, as a unique cultural heritage with a long history of development in my country, is easily adopted and accepted by the Chinese people, and has significant advantages such as simple operation, low cost, low toxicity and side effects, low recurrence rate, and flexible prescription and medication. Summary of the invention

[0006] Purpose of the invention: The technical problem to be solved by the present invention is to address the deficiencies in the prior art and to provide an application of a composition containing Cordyceps militaris extract in the preparation of a product for curing or improving colitis.

[0007] In order to solve the above technical problems, the present invention discloses the following technical solutions:

[0008] In a first aspect, the present invention discloses a composition for preventing and treating colitis, comprising a Cordyceps militaris extract, an Astragalus membranaceus extract, a Sanguisorba officinalis extract, and a Bletilla striata extract.

[0009] Furthermore, the composition also includes any one or a combination of angelica extract, coix seed extract, and raw licorice extract.

[0010] Astragalus has the functions of strengthening the spleen and replenishing the middle, raising yang and lifting the sunken, benefiting the defense and consolidating the exterior, promoting diuresis, expelling toxins and promoting tissue regeneration, and it can strengthen the body and eliminate evil.

[0011] Sanguisorba officinalis has the effects of cooling blood, stopping bleeding, detoxifying and healing sores.

[0012] Baiji has the effects of astringing, stopping bleeding, reducing swelling and invigorating the body.

[0013] Angelica sinensis is pungent, dispersing, warming and unblocking, sweet, moist and nourishing. It is good at replenishing blood, activating blood circulation, relieving pain and moistening the intestines.

[0014] Coix seeds have the effects of strengthening the spleen and lungs, removing dampness, clearing away heat, discharging pus, removing numbness and stopping diarrhea.

[0015] Raw licorice can harmonize various medicines, clear away heat and detoxify, and relieve pain.

[0016] In some embodiments, the weight proportions of each component are as follows: 140-240 parts of Cordyceps militaris extract, 580-680 parts of Astragalus extract, 280-340 parts of Sanguisorba officinalis extract, and 290-340 parts of Bletilla striata extract, preferably 150-230 parts of Cordyceps militaris extract, 590-670 parts of Astragalus extract, 290-330 parts of Sanguisorba officinalis extract, and 300-330 parts of Bletilla striata extract, preferably 160-220 parts of Cordyceps militaris extract, 600-660 parts of Astragalus extract, 310-320 parts of Sanguisorba officinalis extract, and 310-320 parts of Bletilla striata extract.

[0017] In some embodiments, the weight proportions of each component are as follows: 140-180 parts of Cordyceps militaris extract, 580-620 parts of Astragalus extract, 290-330 parts of Sanguisorba officinalis extract, and 300-330 parts of Bletilla striata extract, preferably 150-170 parts of Cordyceps militaris extract, 590-610 parts of Astragalus extract, 300-320 parts of Sanguisorba officinalis extract, and 310-320 parts of Bletilla striata extract, preferably 160 parts of Cordyceps militaris extract, 600 parts of Astragalus extract, 310 parts of Sanguisorba officinalis extract, and 315 parts of Bletilla striata extract.

[0018] In some embodiments, the weight proportions of each component are as follows: 200-240 parts of Cordyceps militaris extract, 640-680 parts of Astragalus extract, 300-340 parts of Sanguisorba officinalis extract, and 300-340 parts of Bletilla striata extract, preferably 210-230 parts of Cordyceps militaris extract, 650-670 parts of Astragalus extract, 310-330 parts of Sanguisorba officinalis extract, and 310-330 parts of Bletilla striata extract, preferably 220 parts of Cordyceps militaris extract, 660 parts of Astragalus extract, 320 parts of Sanguisorba officinalis extract, and 320 parts of Bletilla striata extract.

[0019] In some embodiments, the weight portions of Cordyceps militaris extract and Angelica sinensis extract are 140-240 parts and 180-280 parts, respectively, preferably 150-230 parts and 190-270 parts, preferably 160-220 parts and 200-260 parts; preferably, the weight portions of Cordyceps militaris extract and Coix lachryma-jobi extract are 140-240 parts and 440-540 parts, respectively, preferably 150-230 parts and 450-530 parts, preferably 160-220 parts and 460-520 parts; preferably, the weight portions of Cordyceps militaris extract and raw licorice extract are 140-240 parts and 180-280 parts, respectively, preferably 150-230 parts and 190-270 parts, preferably 160-220 parts and 200-260 parts.

[0020] In some embodiments, the weight portions of Cordyceps militaris extract, Angelica sinensis extract, Coix seed extract, and raw licorice extract are 140-240 parts, 180-280 parts, 440-540 parts, and 180-280 parts, respectively, preferably 150-230 parts, 190-270 parts, 450-530 parts, and 190-270 parts, preferably 160-220 parts, 200-260 parts, 460-520 parts, and 200-260 parts.

[0021] In a second aspect, the present invention discloses a pharmaceutical composition.

[0022] Wherein, the pharmaceutical composition comprises (i) a Cordyceps militaris extract or the composition described in the first aspect, and (ii) a pharmaceutically acceptable excipient.

[0023] The pharmaceutically acceptable excipients are conventional excipients in the art, such as fillers, lubricants, adhesives, etc.

[0024] In a third aspect, the present invention discloses a drug for preventing and treating colitis.

[0025] Wherein, the drug for preventing and treating colitis includes Cordyceps militaris extract or the composition described in the first aspect or the pharmaceutical composition described in the second aspect.

[0026] In a fourth aspect, the present invention discloses the use of a Cordyceps militaris extract or the composition described in the first aspect or the pharmaceutical composition described in the second aspect in the preparation of a drug for preventing and treating colitis.

[0027] The composition provided in the present invention aims at reducing swelling and relieving pain, promoting blood circulation and removing blood stasis, nourishing yin and clearing away heat, strengthening the spleen and warming the kidney, relieving colon inflammation and promoting the repair of the intestinal mucosal barrier.

[0028] The Cordyceps militaris extract described in the present invention is a Cordyceps militaris water extract. In some embodiments, the mass ratio of cordycepin to cordyceps polysaccharide in the Cordyceps militaris extract is 3:2.1-8, preferably 3:3-6, preferably 3:4. In some embodiments, the Cordyceps militaris water extract, in addition to cordycepin and cordyceps polysaccharide, also includes cordycepic acid, cordyceps adenosine, cordyceps polypeptide, amino acid, or any combination of the foregoing. In some embodiments, the mass ratio of cordycepin to cordycepic acid in the Cordyceps militaris water extract is 2.3-3.1:0.5-1.5, preferably 2.5-2.9:0.8-1.2, preferably 2.7:1; in some embodiments, the mass ratio of cordycepin to cordyceps adenosine in the Cordyceps militaris water extract is 23-31:2-6, preferably 25-29:3-5, preferably 27:4; in some embodiments, the mass ratio of cordycepin to cordyceps polypeptide in the Cordyceps militaris water extract is 23-31:2-8, preferably 25-29:3-7, preferably 27:5; in some embodiments, the mass ratio of cordycepin to amino acids in the Cordyceps militaris water extract is 25-29:14-22, preferably 25-29:16-20, preferably 27:18.

[0029] The astragalus extract described in the present invention is an extract of astragalus in a mixed solvent of alcohol and water, the extraction is reflux extraction, the extraction time is 1-3h, the content of ethanol in ethanol and water is 70%-80%, such as 75%, the extraction temperature is 70-100°C, reflux extraction temperature, the extraction time is 1-5h, such as 3h, 4h, and the mass volume ratio of astragalus to solvent is 1g:5-15mL, such as 1g:10mL.

[0030] The Sanguisorba officinalis extract described in the present invention is a water extract of Sanguisorba officinalis, such as that obtained by extracting Sanguisorba officinalis in boiling water for 1-4 hours; the extraction temperature is 70-100° C., the reflux extraction temperature, the extraction time is 1-5 hours, such as 3 hours, 4 hours, and the mass volume ratio of Sanguisorba officinalis to water is 1g:5-15mL, such as 1g:10mL.

[0031] The Bletilla striata extract described in the present invention is a water extract of Bletilla striata, the extraction temperature is 70-100° C., the extraction time is 1-5 h, such as 3 h, 4 h, and the mass volume ratio of Bletilla striata to water is 1 g:5-15 mL, such as 1 g:10 mL.

[0032] The angelica extract of the present invention is an extract of angelica ethanol and water, the content of ethanol in the ethanol and water is 70%-80%, such as 75%, the extraction temperature is 70-100°C, reflux temperature, the extraction time is 1-5h, such as 3h, 4h, and the mass volume ratio of angelica to water is 1g:5-15mL, such as 1g:10mL.

[0033] The coix seed extract of the present invention is a coix seed water extract, the extraction temperature is 70-100°C, the extraction time is 1-5h, such as 3h, 4h, and the mass volume ratio of coix seed to water is 1g:5-15mL, such as 1g:10mL.

[0034] The raw licorice extract of the present invention is a raw licorice water extract, the extraction temperature is 70-100° C., the extraction time is 1-5 h, such as 3 h, 4 h, and the mass volume ratio of raw licorice to water is 1 g:5-15 mL, such as 1 g:10 mL.

[0035] The prevention and treatment mentioned in the present invention include prevention and treatment, such as improvement and cure.

[0036] The present invention has no special requirements for the preparation method of each dosage form of the drug, and conventional methods in the field are all acceptable. It can be prepared according to conventional production methods in the pharmaceutical field, such as mixing the active ingredient with one or more carriers and then making it into the desired dosage form.

[0037] The term "pharmaceutically acceptable" in the present invention refers to those compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0038] Beneficial effects:

[0039] The composition provided by the present invention includes Cordyceps militaris extract, Astragalus extract, Sanguisorba officinalis extract and Bletilla striata extract, which has the purpose of reducing swelling and relieving pain, nourishing yin and clearing heat, strengthening the spleen and warming the kidney, promoting the repair of intestinal mucosal barrier, quickly relieving inflammatory response, and has no effect on body weight. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] The present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments, and the above and / or other advantages of the present invention will become more clear.

[0041] Figure 1 is the colon mucosal morphological injury index (CMDI) score; compared with the blank control group, P ### <0.001; compared with the model group, P *** <0.01; P ** <0.05.

[0042] Figure 2 For myeloperoxidase (MPO) activity detection; compared with the blank control group, P ### <0.001; compared with the model group, P *** <0.01; P ** <0.05.

[0043] Figure 3 ELISA was used to detect related cytokines; compared with the blank control group, P ### <0.001; compared with the model group, P *** <0.01; P ** <0.05.

[0044] Figure 4 Real-time PCR was used to detect the expression levels of IL-6 and IL-10 mRNA in colon tissue; compared with the blank control group, P ### <0.001; compared with the model group, P *** <0.01; P ** <0.05. DETAILED DESCRIPTION

[0045] The present invention can be better understood according to the following examples. However, it is easy for those skilled in the art to understand that the contents described in the examples are only used to illustrate the present invention, and should not and will not limit the present invention described in detail in the claims.

[0046] The experimental methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.

[0047] The composition provided by the present invention aims to reduce swelling and relieve pain, promote blood circulation and remove blood stasis, nourish yin and clear away heat, strengthen the spleen and warm the kidney, promote the repair of intestinal mucosal barrier, quickly relieve inflammatory response, and cure or improve colitis.

[0048] The Cordyceps militaris extract described in the following examples, unless otherwise specified, comprises the following components in percentage by mass: 27% cordycepin, 10% cordycepic acid, 4% cordyceps adenosine, 36% cordyceps polysaccharide, 5% cordyceps polypeptide, and 18% amino acids.

[0049] The preparation methods of the astragalus extract, sanguisorba officinalis extract, bletilla striata extract, angelica extract, coix seed extract, and raw licorice extract described in the following examples are as follows:

[0050] Preparation of Astragalus extract: Astragalus was placed in a vacuum drying oven at 50°C for 24 h, crushed, passed through a 60-mesh sieve, and mixed to a solid-liquid ratio of 10:1 (mL g -1 ) Add 75% ethanol, reflux extraction twice, 1 hour each time, combine the extracts, filter, concentrate using a rotary evaporator (<50℃), and freeze-dry to a lyophilized powder.

[0051] Preparation of Sanguisorba officinalis extract: Place Sanguisorba officinalis in a vacuum drying oven at 50°C for 1 day, crush, pass through a 60-mesh sieve, add distilled water at a solid-liquid ratio of 1:10 (g / mL), extract under boiling water bath reflux for 3 times, each time for 1 hour, filter, and combine the filtrate. The filtrate is concentrated by rotary evaporation, and the concentrate is freeze-dried and crushed.

[0052] Preparation of Bletilla striata extract: Place Bletilla striata in a vacuum drying oven at 50°C for 1 day, crush, pass through a 60-mesh sieve, add distilled water at a solid-liquid ratio of 1:10 (g / mL), extract under boiling water bath reflux for 3 times, each time for 1 hour, filter, and combine the filtrate. The filtrate is concentrated by rotary evaporation, and the concentrate is freeze-dried and crushed.

[0053] Preparation of Angelica extract: Angelica was placed in a vacuum drying oven at 50°C for 24 h, crushed, passed through a 60-mesh sieve, and mixed to a solid-liquid ratio of 10:1 (mL·g -1 ) Add 75% ethanol, reflux extraction twice, 1 hour each time, combine the extracts, filter, concentrate using a rotary evaporator (<50℃), and freeze-dry to a lyophilized powder.

[0054] Preparation of coix seed extract: Place coix seed in a vacuum drying oven at 50°C for 1 day, crush, pass through a 60-mesh sieve, add distilled water at a solid-liquid ratio of 1:10 (g / mL), extract under boiling water bath heat reflux for 3 times, each time for 1 hour, filter, and combine the filtrate. The filtrate is concentrated by rotary evaporation, and the concentrate is freeze-dried and crushed.

[0055] Preparation of raw licorice extract: Place the raw licorice in a vacuum drying oven at 50°C for 1 day, crush it, pass it through a 60-mesh sieve, add distilled water at a solid-liquid ratio of 1:10 (g / mL), extract it under boiling water bath reflux for 3 times, each time for 1 hour, filter it, and combine the filtrate. The filtrate is concentrated by rotary evaporation, and the concentrate is freeze-dried and crushed.

[0056] The specific method for preparing the composition by extraction in the following examples and comparative examples is to prepare each extract according to the above method, and then weigh the freeze-dried powder according to their respective mass ratios.

[0057] Example 1

[0058] A composition consists of the following components in parts by weight: 160 parts of Cordyceps militaris extract, 600 parts of Astragalus membranaceus extract, 310 parts of Sanguisorba officinalis extract and 315 parts of Bletilla striata extract.

[0059] Example 2

[0060] A composition consists of the following components in parts by weight: 160 parts of Cordyceps militaris extract, 600 parts of Astragalus extract, 310 parts of Sanguisorba officinalis extract, 310 parts of Bletilla striata extract, 200 parts of Angelica sinensis extract, 460 parts of Coix seed extract and 200 parts of raw liquorice extract.

[0061] Example 3

[0062] A composition consists of the following components in parts by weight: 220 parts of Cordyceps militaris extract, 660 parts of Astragalus membranaceus extract, 320 parts of Sanguisorba officinalis extract and 320 parts of Bletilla striata extract.

[0063] Example 4

[0064] A composition consists of the following components in parts by weight: 220 parts of Cordyceps militaris extract, 660 parts of Astragalus extract, 320 parts of Sanguisorba officinalis extract, 320 parts of Bletilla striata extract, 260 parts of Angelica sinensis extract, 520 parts of Coix seed extract and 260 parts of raw liquorice extract.

[0065] Comparative Example 1

[0066] A composition consists of the following components in parts by weight: 160 parts of American ginseng extract, 600 parts of astragalus extract, 310 parts of sanguisorba officinalis extract and 315 parts of bletilla striata extract.

[0067] Comparative Example 2

[0068] A composition consists of the following components in parts by weight: 160 parts of Cordyceps militaris extract, 600 parts of American ginseng extract, 310 parts of raw liquorice extract and 315 parts of Bletilla striata extract.

[0069] Comparative Example 3

[0070] Cordyceps polysaccharide.

[0071] Example 5

[0072] The cordyceps militaris extract comprises the following components: 27% cordycepin, 10% cordycepic acid, 4% cordyceps adenosine, 36% cordyceps polysaccharide, 5% cordyceps polypeptide and 18% amino acid.

[0073] Example 6

[0074] The cordyceps militaris extract comprises the following components: 27% cordycepin, 5% cordycepic acid, 2% cordyceps adenosine, 30% cordyceps polysaccharide, 2% cordyceps polypeptide and 23% amino acid.

[0075] Example 7

[0076] The cordyceps militaris extract comprises the following components: 27% cordycepin, 15% cordycepic acid, 6% cordyceps adenosine, 45% cordyceps polysaccharide, 8% cordyceps polypeptide and 13% amino acid.

[0077] Application Example: Experiment on the curative effect of each composition on colitis in C57BL / 6J mice

[0078] 1. Experimental Methods

[0079] SPF male C57BL / 6 mice, weighing 19-20 grams, were randomly divided into a blank control group, a model group, a positive control group, a test group (Example 1-7 groups), and a comparison group (Comparative Example 1-3 groups), with 5 mice in each group. The blank control group drank purified water, and the other groups drank 2.5% dextran sulfate sodium aqueous solution (DDS) to induce colitis models for 7 consecutive days. The positive control group, the test group and the comparison group were given drugs from the first day after the model was successfully established. The positive control group (sulfasalazine enteric-coated tablets were ground and dissolved in water, and administered by gavage at a dosage of 125 mg / kg / d), the test group (Example 1-4 groups, administered by gavage at a dosage of 1.7 g / kg / d; Example 5-7 groups, administered by gavage at a dosage of 200 mg / kg / d), the comparison group (Comparative Example 1-2 groups, administered by gavage at a dosage of 1.7 g / kg / d; Comparative Example 3 group, administered by gavage at a dosage of 200 mg / kg / d), the model group and the blank control group were gavaged with 10 ml / kg / d of normal saline, and then fed continuously for 7 days.

[0080] 2. Detection indicators and methods

[0081] General status and disease activity index (DAI) scoring: The weight, stool texture, occult blood or bloody stool characteristics of mice were recorded from the first day of successful modeling, and the DAI score was calculated according to Table 1, DAI = (weight loss score + stool texture score + stool occult blood score) / 3, and the scoring criteria are shown in Table 1.

[0082] Table 1 DAI score table

[0083]

[0084] Colon mucosal gross morphological injury index (CMDI) scoring: On the 7th day after successful modeling, mice were fasted for 1 day. After 3% sodium pentobarbital anesthesia, blood was collected from the inferior vena cava and stored in a -80°C refrigerator for later use. The mice were killed, and the entire colon and rectum from the anus to the end of the cecum were removed, cut longitudinally along the mesentery, rinsed with saline, and dried. The gross damage and scoring of the colon mucosa were observed. The two most severely affected lesions of 0.5 cm colon tissue were taken and fixed in 4% paraformaldehyde solution to observe the mucosal damage. The rest of the colon was placed in a -80°C refrigerator for later use. The scoring criteria are shown in Table 2.

[0085] Table 2 CMDI scoring criteria

[0086]

[0087] Myeloperoxidase (MPO) activity detection: MPO is a heme protease that can represent the degree of neutrophil infiltration. The severity of colonic inflammatory response can be assessed by measuring MPO enzyme activity. Weigh 100 mg of colon tissue, add 1 ml of normal saline, grind into colon tissue homogenate, centrifuge at 12000r / min for 10 minutes at low temperature, take the supernatant, add it to a 96-well plate, add 50μL TM colorimetric solution, and react at room temperature for 5 minutes. Add 50μL of concentrated sulfuric acid to terminate the reaction. Use an enzyme reader to measure OD 450 Absorbance value.

[0088] ELISA detection of related cytokines: serum was taken from a -80℃ refrigerator, centrifuged at 4℃, 3000r / min for 10min, and the supernatant was taken. The ELISA kit was operated according to the instructions. The absorbance at 450nm was measured with an enzyme marker and the concentrations of IL-6, IL-10, and TNF-α were calculated.

[0089] Real-time PCR was used to detect the expression levels of IL-6 and IL-10 mRNA in colon tissue: 40 mg of intestinal tissue was collected and ground into colon tissue homogenate. 1 ml of Trizol was added and incubated on ice for 10 min. The mRNA was extracted and reverse transcribed into cDNA according to the reverse transcription kit steps. The cDNA was used as a template for amplification, GAPDH was used as an internal reference, and 2 -ΔΔCt The relative expression of each target gene mRNA was analyzed by qRT-PCR. The expression levels of IL-6 and IL-10 mRNA in colon tissue were detected by qRT-PCR. The primers for qRT-PCR are shown in Table 3.

[0090] Table 3 qRT-PCR primers

[0091]

[0092] 3. Experimental results

[0093] (1) General condition and disease activity index (DAI) score

[0094] Table 4 Comparison of body weight and DAI scores of mice in each group (x±s, points)

[0095]

[0096] Note: Compared with the blank control group, P ### <0.001; compared with the model group, P *** <0.01; P ** <0.05.

[0097] It can be seen from the results that the weight of mice in the model group was significantly lower than that of the blank control group one week after successful modeling (P < 0.001); compared with the model group, the weight of the positive control group, Example 1-7 group and Comparative Example 2 group increased significantly (P < 0.01, P < 0.05); the weight of mice in Comparative Example 1 and Comparative Example 3 groups showed an upward trend, but there was no significant difference. The DAI score of mice in the model group was 3.73 ± 0.1 (P < 0.001), which was significantly lower than that of the blank control group; compared with the model group, the DAI score of the positive control group was significantly reduced (P < 0.01), and the DAI scores of Example 1-7 group and Comparative Example 2 group were greatly reduced (P < 0.05); the DAI scores of mice in Comparative Example 1 and Comparative Example 3 groups decreased, but there was no significant difference. Studies have shown that Example 1-7 group and Comparative Example 2 group can improve the weight loss of colitis mouse models.

[0098] (2) Colonic mucosal morphological injury index (CMDI) score

[0099] like Figure 1 As shown, compared with the blank control group, the colon tissue of the model group mice was dark red under naked eye observation, the submucosal layer was obviously edematous, different degrees of ulcer surface were visible, and CMDI was significantly increased (P<0.001); compared with the model group, the color and edema of the colon tissue of the positive control group, the examples 1-3 groups, the examples 5-7 groups and the comparative example 2 group were improved, and the CMDI was greatly reduced (P<0.05); the CMDI score of the example 4 group was significantly reduced (P<0.01); the CMDI of the comparative example 1 and the comparative example 3 groups decreased but there was no significant difference. The study showed that the examples 1-7 groups and the comparative example 2 group can improve the clinical symptoms of UC mouse model such as colon bleeding and ulcer.

[0100] (3) Myeloperoxidase (MPO) activity detection

[0101] like Figure 2 As shown, compared with the blank control group, the MPO of the model group mice increased significantly (P<0.001); compared with the model group, the MPO of the Example 4 group decreased significantly (P<0.01); the MPO scores of the positive control group, the Example 1-3 groups, the Example 5-7 groups and the Comparative Example 2 group decreased (P<0.05); the Comparative Example 1 and the Comparative Example 3 groups decreased, but there was no significant difference. The study showed that the Example 1-7 groups and the Comparative Example 2 group can alleviate colon inflammation in UC mouse models.

[0102] (4) ELISA detection of related cytokines

[0103] like Figure 3As shown in Figures ac, compared with the blank control group, the serum IL-6 and TNF-α levels of the model group mice were significantly increased (all P < 0.001), and the serum IL-10 level was significantly reduced (P < 0.001); compared with the model group, the serum IL-6 and TNF-α levels of the positive control group, Example 1-7 group and Comparative Example 2 group mice were significantly reduced (P < 0.01, P < 0.05), and the serum IL-10 level was significantly increased (P < 0.01, P < 0.05); the IL-6 and TNF-α levels of the mice in Comparative Example 1 and Comparative Example 3 groups showed a downward trend, and the serum IL-10 level showed an upward trend, but there was no significant difference. The study showed that the Example 1-7 group and the Comparative Example 2 group can promote the repair of the colon mucosa in the colitis mouse model.

[0104] (5) Real-time PCR detection of IL-6 mRNA and IL-10 mRNA expression levels in colon tissue

[0105] like Figure 4 As shown in ab, compared with the blank control group, the expression level of IL-6 mRNA in the colon tissue of the model group mice was significantly increased (P < 0.001), and the expression level of IL-10 mRNA was significantly decreased (P < 0.001). Compared with the model group, the expression level of IL-6 mRNA in the positive control group, the Example 1-7 group and the Comparative Example 2 group was reduced, and the expression level of IL-10 mRNA was increased (P < 0.01, P < 0.05); the expression level of IL-6 mRNA in the Comparative Example 1 and Comparative Example 3 groups showed a downward trend, and the expression level of IL-10 mRNA showed an upward trend, but there was no significant difference. Studies have shown that the Example 1-7 group and the Comparative Example 2 group can promote the expression of inflammatory factors in the colon mucosa of the colitis mouse model and promote mucosal repair.

[0106] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A composition for preventing and treating colitis, characterized in that: Including Cordyceps militaris extract, Astragalus extract, Sanguisorba officinalis extract, and Bletilla striata extract.

2. The composition according to claim 1, characterized in that The weight proportions of each component are as follows: 140-240 parts of Cordyceps militaris extract, 580-680 parts of Astragalus extract, 280-340 parts of Sanguisorba officinalis extract, and 290-340 parts of Bletilla striata extract, preferably 150-230 parts of Cordyceps militaris extract, 590-670 parts of Astragalus extract, 290-330 parts of Sanguisorba officinalis extract, and 300-330 parts of Bletilla striata extract, preferably 160-220 parts of Cordyceps militaris extract, 600-660 parts of Astragalus extract, 310-320 parts of Sanguisorba officinalis extract, and 310-320 parts of Bletilla striata extract.

3. The composition according to claim 1 or 2, characterized in that The Cordyceps militaris extract is a water extract of Cordyceps militaris; preferably, the mass ratio of cordycepin to cordyceps polysaccharide in the Cordyceps militaris extract is 3:2.1-8, preferably 3:3-6, and preferably 3:

4.

4. A composition according to any one of claims 1 to 3, characterized in that It also includes any one or a combination of angelica extract, coix seed extract, and raw licorice extract.

5. The composition according to claim 4, characterized in that The weight portions of Cordyceps militaris extract and Angelica sinensis extract are 140-240 parts and 180-280 parts, respectively, preferably 150-230 parts and 190-270 parts, preferably 160-220 parts and 200-260 parts; preferably, the weight portions of Cordyceps militaris extract and Coix lachryma-jobi extract are 140-240 parts and 440-540 parts, respectively, preferably 150-230 parts and 450-530 parts, preferably 160-220 parts and 460-520 parts; preferably, the weight portions of Cordyceps militaris extract and raw licorice extract are 140-240 parts and 180-280 parts, respectively, preferably 150-230 parts and 190-270 parts, preferably 160-220 parts and 200-260 parts; Preferably, the weight portions of Cordyceps militaris extract, Angelica sinensis extract, Coix seed extract and raw licorice extract are 140-240 parts, 180-280 parts, 440-540 parts and 180-280 parts respectively, preferably 150-230 parts, 190-270 parts, 450-530 parts and 190-270 parts, preferably 160-220 parts, 200-260 parts, 460-520 parts and 200-260 parts.

6. A pharmaceutical composition for preventing and treating colitis, characterized in that: The invention comprises (i) the composition or Cordyceps militaris extract according to any one of claims 1 to 4, and (ii) a pharmaceutically acceptable excipient.

7. The pharmaceutical composition according to claim 6, characterized in that: The Cordyceps militaris extract is a water extract of Cordyceps militaris; preferably, the mass ratio of cordycepin to cordyceps polysaccharide in the Cordyceps militaris extract is 3:2.1-8, preferably 3:3-6, and preferably 3:

4.

8. A drug for preventing and treating colitis, characterized in that: The invention comprises a Cordyceps militaris extract or a composition according to any one of claims 1 to 4 or a pharmaceutical composition according to claim 6 or 7; preferably, the Cordyceps militaris extract is a Cordyceps militaris water extract; preferably, the mass ratio of cordycepin to cordyceps polysaccharide in the Cordyceps militaris extract is 3:2.1-8, preferably 3:3-6, and preferably 3:

4.

9. Use of the composition according to any one of claims 1 to 4, the pharmaceutical composition according to claim 6 or 7, or the Cordyceps militaris extract in the preparation of a medicament for preventing and treating colitis.

10. The use according to claim 9, characterized in that: The Cordyceps militaris extract is a water extract of Cordyceps militaris; preferably, the mass ratio of cordycepin to cordyceps polysaccharide in the Cordyceps militaris extract is 3:2.1-8, preferably 3:3-6, and preferably 3:4.

Images